6:01 AM ET
8-K
Nasdaq/NYSE Compliance Notice
Tempest Therapeutics Nasdaq/NYSE Compliance Notice
Tempest Therapeutics received a deficiency notice from Nasdaq on November 4, 2026, because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 3, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. The notice has no immediate effect on the listing of the company's common stock.
- Counterparty
- Nasdaq
- Term
- 180 days